Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Consensus Price Target of $36.80 According to Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have earned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $36.80.

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price target on shares of Kyntra Bio in a research note on Tuesday, September 1st. Oppenheimer started coverage on Kyntra Bio in a research note on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Maxim Group began coverage on Kyntra Bio in a research note on Tuesday. They issued a “buy” rating and a $35.00 price objective for the company. Lake Street Capital began coverage on Kyntra Bio in a report on Thursday, September 17th. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, Weiss Ratings lowered Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday.

Institutional Investors Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio at the end of the most recent quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

Kyntra Bio Price Performance

Shares of Kyntra Bio stock opened at $5.87 on Wednesday. The stock has a market capitalization of $23.77 million, a P/E ratio of 0.13 and a beta of 1.05. The business has a 50 day simple moving average of $7.26 and a two-hundred day simple moving average of $7.12. Kyntra Bio has a 12 month low of $5.62 and a 12 month high of $11.65.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.